Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2018-05-04
- Target Recruit Count
- 80
- Registration Number
- NCT02559154
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 150
- Registration Number
- NCT02555839
- Locations
- 🇦🇹
AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie, Vienna, Austria
🇦🇹LKH Feldkirch, Intern E, Hämatologie, Feldkirch, Austria
🇦🇹SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH, Salzburg, Austria
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02542111
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Immune Modulation Therapy for Pompe Disease
- Conditions
- Interventions
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02525172
- Locations
- 🇨🇳
Yin-Hsiu Chien, Taipei, Taiwan
Quantitating the Impact of Plerixafor
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- E. Steve Woodle
- Target Recruit Count
- 12
- Registration Number
- NCT02522572
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 14
- Registration Number
- NCT02514382
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
- Conditions
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT02513186
- Locations
- 🇫🇷
Investigational Site Number : 250003, Pierre Benite, France
🇫🇷Investigational Site Number : 250002, Nantes Cedex 01, France
🇫🇷Investigational Site Number : 250001, TOULOUSE Cedex 9, France
Belimumab Impacting Transplant Eligibility
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- E. Steve Woodle
- Target Recruit Count
- 11
- Registration Number
- NCT02500251
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.